Conditions: Carcinoma, Hepatocellular
Keywords: HCC Cancer Liver Cancer TACE
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 458
Healthy volunteers: no

Brief summary:
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.

Detailed description:

Arms:
arm 1: Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity. arm 2: Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).

Interventions: intervention 1: Sorafenib (Nexavar, BAY43-9006) intervention 2: Placebo
Intervention descriptions: intervention 1: Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib intervention 2: Placebo: matching placebo

Protocol document: